165 related articles for article (PubMed ID: 38493435)
1. Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.
Matsushima H; Taguchi T; Kodama S; Okubo N; Saito K; Jabłońska K; Fukumoto S; Matsumoto T
J Bone Miner Metab; 2024 Mar; 42(2):223-232. PubMed ID: 38493435
[TBL] [Abstract][Full Text] [Related]
2. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
3. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
Wallander M; Axelsson KF; Lundh D; Lorentzon M
Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
[TBL] [Abstract][Full Text] [Related]
4. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
[TBL] [Abstract][Full Text] [Related]
5. Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score.
Kawahara T; Fusayasu S; Izumi K; Yokomizo Y; Ito H; Ito Y; Kurita K; Furuya K; Hasumi H; Hayashi N; Myoshi Y; Miyamoto H; Yao M; Uemura H
BMC Urol; 2016 Jun; 16(1):32. PubMed ID: 27316330
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
7. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
9. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea.
Kim DK; Lee HS; Park JY; Kim JW; Ahn HK; Ha JS; Cho KS
Sci Rep; 2021 May; 11(1):10057. PubMed ID: 33980958
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
[TBL] [Abstract][Full Text] [Related]
12. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
13. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
Lee CH; Huang G; Chan PH; Hai J; Yeung CY; Fong CH; Woo YC; Ho KL; Yiu MK; Leung F; Lau TW; Tse HF; Lam KS; Siu CW
PLoS One; 2017; 12(2):e0171495. PubMed ID: 28158241
[TBL] [Abstract][Full Text] [Related]
16. Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study.
Tae BS; Jeon BJ; Choi H; Bae JH; Park JY
Cancer Med; 2019 Aug; 8(9):4475-4483. PubMed ID: 31183968
[TBL] [Abstract][Full Text] [Related]
17. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
Morgans AK; Smith MR; O'Malley AJ; Keating NL
Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
[TBL] [Abstract][Full Text] [Related]
18. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
20. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.
Kirk PS; Borza T; Shahinian VB; Caram MEV; Makarov DV; Shelton JB; Leppert JT; Blake RM; Davis JA; Hollenbeck BK; Sales A; Skolarus TA
BJU Int; 2018 Apr; 121(4):558-564. PubMed ID: 29124881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
